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Abstract Modiﬁcation of cancer cells likely to reduce
their immunogenicity, including loss or down-regulation of
MHC molecules, is now well documented and has become
the main support for the concept of immune surveillance.
The evidence that these modiﬁcations, in fact, result from
selection by the immune system is less clear, since the
possibility that they may result from reorganized metabo-
lism associated with proliferation or from cell de-differ-
entiation remains. Here, we (a) survey old and new
transplantation experiments that test the possibility of
selection and (b) survey how transmissible tumours of dogs
and Tasmanian devils provide naturally evolved tests of
immune surveillance.
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Introduction
Immune evasion has been found in at least ﬁve animal
cancer models. The panel includes (a) transplantation of
methylcholanthrene (MCA) tumours from F1 donors to
parental strain congenic mice [1, 2], (b) occult cancer
induced in mice by ultra-low doses of MCA [3], (c)
immunoselection in metastases of transplantable mouse
tumours, (d) the canine transmissible venereal tumour
(CTVT) [4] and (e) the transmissible tumour of Tasmanian
devils (devil facial tumour disease, DFTD) [5, 6]. Here, we
survey these instances, enquiring how they bear at present
on human cancer, and what they may reveal in the future.
Our assumption is that intense selective pressure acting on
these cancer cells evokes (via mutation and selection) a
wide range of defensive strategies that enable them to sur-
vive immunological attack, as well as some that actively
impair the host’s attack machinery. The most important
contribution from these animal models may be to validate
the claims for immunoselection in cancer suggesting new
avenues of research to investigate this problem in human
cancers [7, 8]. Those modiﬁcations leading to immune
escape that emerge in both the animal models and human
cancers will be substantiated as likely due to immunose-
lection, while the status of those that do not do so will be
called in question. The latter may to an unknown extent
simply reﬂect de-differentiation or metabolic change asso-
ciated with the proliferative activity of cancer cells. After
all, changes in the level of MHC antigen (hereafter MHC)
expression that in cancer cells are accepted as a hallmark of
immune evasion also occur elsewhere, notably in foetal
cells at the foetal–maternal interface [9], in embryonic stem
cells and in neural progenitor cells [10–12].
Histocompatibility variants in mice: a historical
perspective
During the 1920s, Little and Snell [13] began to explore
systematically the use of inbred mouse strains to explore
the rules of histocompatibility. They established that
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inbred strain and its F1 hybrids, but not into other strains.
Tumours originating in an F1 hybrid could be transplanted
within the same hybrids but not into either of the parental
strains. Thus, Haldane noted, the histocompatibility factors
that governed transplantation behave as primary gene
products that might serve as antigens, a suggestion that was
later veriﬁed by Gorer and Snell. Snell [13] continued the
analysis of histocompatibility by breeding mouse strains
that differed from one another at single histocompatibility
loci, his so-called congenic strains (although we now know
that each MHC is a composite of several closely linked
genes). The availability of these congenic strains prompted
two groups to use them to test the genetic stability of these
MHC antigens [1, 2]. The studies were carried out in dif-
ferent mouse strains and were entirely independent, but
yielded essentially identical results illustrated in Table 2.
Prior to rejection in an MHC incompatible strain tumour
transplants grow for a few days, thus generating a popu-
lation of cells that come under intense selection for loss of
their MHC antigens. Both studies found that under these
conditions, tumours of F1 origin (i.e. MHC-heterozygous)
regularly lost expression of the MHC antigen(s) foreign to
the host, whereas MHC-homozygous cells failed to do so.
The loss was permanent and heritable, remaining evident
after passage through the neutral F1 host. It contrasts with
the consistent behaviour of the many MHC-homozygous
tumours that Snell had used to derive the MHC-congenic
strains, where antigen-loss would have been fatal to his
enterprise. Loss of the MHC antigens was further validated
by serology, showing that the variant tumour cells neither
reacted with antisera directed against the missing MHC
antigens nor proved to be able to elicit such antibodies [2].
Furthermore, the variant cells grew in pre-immunized
hosts, where even weak expression of the missing antigens
would have been detected. Providing further evidence of
mutation, the cells derived from heterozygous tumours
increased their frequency of take in the parental hosts after
X-irradiation. Thus, the evidence for genetic change (or
possible stable epigenetic change) is strong, but in neither
study was this the only possibility. Not all F1 tumours
yielded straightforward allele-loss variants [2], as found in
the small study illustrated in Table 2 taken from [1].
These ﬁndings were interpreted at the time in terms of
single gene mutation. Later, this interpretation was exclu-
ded when the mouse MHC was found to include several
major polymorphic genes (H2K, H2D, H2A, H2E). It now
seems likely that the loss of heterozygosity (LoH) occurred
through recombination, although chromosome loss may
also have contributed, as previously recorded in long-
transplanted ‘‘non-speciﬁc’’ mouse tumours by Sachs and
Gallily and by Hauschka and Levan, in early work cited in
[2]. These early studies are precursors of the systematic
work on human tumours that has revealed that both chro-
mosome loss and somatic recombination occur frequently
in human tumours [14]. A recent development is the
molecular characterization of a recombination hot spot in
the mouse MHC, which is present in some but not all
haplotypes [15].
Occult sarcoma induced by low dose
methylcholanthrene
Treatment of mice with ultra-low doses of the carcinogen
30-methylcholanthrene (MCA) induces not only a few
cancers of usual type, but also some of occult type that
grow out only in the presence of concomitant immuno-
suppression [3]. This does not occur if the mice are
immunocompromised right from the start of tumour
induction, using RAG-knockout mice. In further tests,
certain monoclonal antibodies proved effective in com-
promising this selection mediated by the immune system
(as annotated in Table 1), while others did not. The system
represents an extension of a broad range of previous work
demonstrating that MCA tumours in mice undergo immu-
noselection, cited in [3]. It is likely to prove useful in future
work, for sorting out the modalities of immune intervention
able to mediate or inhibit selection of tumour variants. We
look forward to a comprehensive annotation of Table 1,
noting validation or exclusion over an expanded range of
evasion mechanisms.
Metastases of chemically induced mouse tumour
undergo immunoselection in normal but not
in athymic (nude) mice
Metastatic tumour variants derived from transplants into
normal hosts regularly lost MHC class I expression, while
cells from similar transplants into immunocompromised
(athymic nude) mice did not do so [16]. The loss of MHC
expression is associated with loss of mRNA for the APM
proteins identiﬁed in Table 1.
Canine transmissible venereal tumour (CTVT)
and transmissible tumour of Tasmanian devils (DFTD)
CTVT was ﬁrst described in 1876 by Novinski [17] and is a
transmissible cancer. Natural transmission of CTVT
between dogs usually occurs through coitus, but also by
biting or licking tumour-affected areas [18]. The tumour
can also be transplanted experimentally between dogs.
Generally, CTVT grows on the external genitalia and may
also metastasize internally and spread to other mucosal
surfaces, although this is a rare event, occurring mainly in
puppies, immunodepressed or previously sick dogs [18].
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tumour cell itself is the transmissible agent responsible for
CTVT [4] and, on the basis of microsatellite and mtDNA
variation analysis, it has been possible to estimate the age
of CTVT at between 250 and 2,500 years or earlier [4, 19].
CTVT thus represents the oldest known cancer cell lineage.
Genetic analysis on microsatellite and DLA alleles indicate
that CTVT most likely originated in wolves and it has been
hypothesized that the inbred nature of some wolf groups
might have facilitated the initial spread of this transmissi-
ble cancer, similar to the facial tumour in Tasmanian devils
[4]. However, further evolution towards immunological
escape must have occurred in CTVT to allow its spread to a
wider dog population.
Remarkably, transplanted CTVT shows a phase of
progressive growth, followed by spontaneous regression
after 3–9 months in most dogs, unless the animal is in poor
condition [18, 20]. Hence, CTVT is characterized clinically
by a progressive, a stationary and regressive phases.
Recovered dogs are immune to tumour growth upon
reinoculation. Irradiation of dogs before CTVT is trans-
planted experimentally increases tumour malignancy, pre-
sumably due to host immunosuppression [20]. The
pathology suggests that tumour-inﬁltrating lymphocytes
(TIL) and macrophages may promote CTVT regression
[21, 22] and overall, the available data suggest that the
immune system plays an important role in regression of
CTVT. Because CTVT is clonal and it is genetically stable
[4], we hypothesize that changes leading to regression must
be regulated epigenetically.
The DFTD is another form of transmissible cancer that
is becoming highly prevalent in Tasmanian devils (Sar-
cophilus harrisii), a marsupial carnivore widespread in
Tasmania [23]. First described in 1996, DFTD appears to
be more recent than CTVT and, in contrast to CTVT, does
not regress. In fact, DFTD is almost invariably deadly
within 6 months of transmission and is causing a rapid
decline of the devil’s population [23]. The tumour affects
facial areas and causes death presumably by suffocation
and extreme difﬁculty in feeding. Transmission occurs by
Table 1 Candidate mechanisms of immune evasion
Gene Function
MHC I (HLA-A, B, C)
d [44, 67, 68] Targeting of CD8 T cell (CTL)
b2-Microglobulin
d [44, 69] MHC I expression
Proteasome components: delta, MB1, Z; LMP’s
c [45, 69]
Chaperones: calnexin
c, ERp57, calreticulin
d [69]
Peptide transporters: TAP1
c and TAP2
c [45, 69]
Antigen processing machinery (APM)
(MHCII) HLA-DR [43] Targeting of CD4 T cell
Whole MHC (Loss of heterozygosity) [27, 28] Immune evasion
HLA-G [70] Targeting of regulatory T cell (Treg). Inhibits
NK-cell function. Protects trophoblast
Deaf1 transcription regulator [46] Suppresses expression of peripheral tissue antigens
FoxP3
?Tregs [51, 71] Protect against autoimmunity
CTLA-4 [72, 73] Down-regulatory
Th17 cells [74] Modulate other tumour-inﬁltrating T cells
KIRs and other NK-cell receptors
b [47, 75] Modulate NK cells
NKG2D
b and other NKT-cell receptors [48, 76] Activating receptor on NK and NKT cells
IL12 [77]
a Required for NKT-cell activation
TGFb1[ 78] Immuno-regulatory
IL-10 [77] Immuno-regulatory
IDO indoleamine-2,3-dioxygenase [79, 80] Immuno-regulatory
IFN-c [79] CTL-upregulatory
IFNGR down-regulation, truncated dominant- negative form [81] Down-regulatory
Fas Ligand [82] Mediates Fas–FasL CTL cytotoxicity
TRAIL [82]
b Mediates CTL cytotoxicity
STAT3/STAT4 [83] Promotes tumour growth, inhibits immunity
a Effective target in the occult cancer system [3]
b Ineffective in the occult cancer system
c Effective target in the mouse metastasis system [16]
d Ineffective in the metastasis system [81]
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123biting in the facial area during frequent ﬁghts or mating.
Genetic and karyotype analyses indicate that DFTD is also
transmitted as a cellular parasite, though the evidence
supporting its clonality is not as strong as in the case of
CTVT [24, 25]. DFTD transmission within the devil pop-
ulation is presumably greatly facilitated by the low diver-
sity of MHC alleles [25]. Whether DFTD is subject to
immunoselection has been questioned, on the grounds that
the population of devils in which it occurs lacks diversity at
the MHC as a consequence of demographic factors: a
population bottleneck and inbreeding. Wild devils show
limited sequence diversity at the MHC, and their mixed
lymphocyte reaction (MLR) is low [6]. However the cru-
cial test of skin graft survival has not been applied, so the
spread of DFTD may yet reﬂect, in part at least, immu-
noselection of the tumour phenotype.
Mechanisms of immune evasion
The main genetic mechanisms thought to mediate immune
evasion are listed in Table 1. Although not comprehensive,
we suggest that this list may help guide future research on
immunoselection in the CTVT and DFTD models pre-
sented here. It is likely that future work in these models
will rely largely on molecular and DNA technologies, so
we mention that apart from HLA-G, all the genes listed in
the table have known orthologs in the dog, and nearly all
also in the opossum, the closest relative of the Tasmanian
devil included in the ENSEMBL database. In this con-
nection, we return to the caveat already mentioned. The
loss of a key immunological molecule such as an MHC is
not necessarily a consequence of immunoselection, since
cancer cells may simply refocus their metabolic machinery
elsewhere. Cancer cells may also undergo a progressive de-
differentiation process, becoming more similar to embry-
onic stem cells or to some stem cell types that express very
little if any MHC class I and II molecules on their surface
[10–12]. The other caveat is that CTVT and DFTD are
allografts, hence they may be subject to greater immuno-
logical selective pressure than normal cancers; yet these
transmissible cancers have been in continuous propagation
in natural conditions over long period of time and are
therefore likely to be very informative on the evolutionary
strategies developed by cancer cells to evade
immunosurveillance.
Loss of MHC genes
The high level of variation at and around the MHC makes
LoH (loss of heterozygosity) relatively easy to detect.
Frequent loss has been detected in biopsies [14] and in
cell lines from carcinoma [26] and melanoma [27, 28],
and in leukemic blasts from relapse but not from fresh
cases [29]. A recent study [30] provides a spectacular
example of LoH in man, where cancer cells passed across
the placenta loose the entire MHC haplotype not inherited
by the infant.
In comparison, little is known about LoH in normal
cells. An obvious question is whether it occurs when HLA-
heterozygous bone marrow cells after haploidentical bone
marrow transplantation, now a common form of therapy in
cancer and (more rarely) in congenital hemopoietic disease
[31]. LoH should be detectable by FACS analysis [29],
provided that the transplanted cells can be identiﬁed by a
marker other than their MHC. An extensive recent study of
transplantation of haploidentical donor T cells for acute
myeloid leukemia or myelodysplastic syndrome provides a
striking example of immunoselection. Relapse was asso-
ciated with the presence of mutant variants of the original
leukemic cells, in which the HLA haplotype that differed
from the donor’s haplotype had been lost [32].
LoH could not account for the ability of CTVT to grow
in a wide range of hosts, although it could enable it to grow
in a limited range of closely inbred dog breeds. In princi-
ple, LoH might have contributed to the initial transmission
of the tumour within members of closely inbred wolf
groups [4, 19]. Genetic analyses showed that CTVT has the
same DLA haplotype worldwide and that most class II
DLA genes were diploid in CTVT, except the DQB1 and
DQA1 loci, which were haploid but only in about 50% of
the tumours analysed [4]. Thus, even if LoH is relatively
frequent in CTVT, it does not seem to have contributed to a
founder effect and we suppose that this would not provide a
signiﬁcant selective advantage, at least in this model.
Reduced MHC class I expression
MHC class I (MHC I) expression can be suppressed by loss
of expression of b2-microglobulin (b2M). b2M is an
invariant single domain protein that binds to and stabilizes
the larger 3-domain, antigen-binding, variable a-chain
component of MHC I. Loss of b2M causes loss of MHC I
expression. Attention is now directed also to the antigen
processing machinery (APM), where the key molecules
responsible for reduced expression in tumours are listed in
Table 1. As a rule the proteasome itself cannot be modi-
ﬁed, because it forms a key part of the machinery for
eliminating defective self-proteins, but the self-peptides
produced by proteasomes, prior to binding to MHC I
molecules pass down a chain of auxiliary molecules that
are often down-regulated in cancer cells.
CTVT has been shown to have little b2-microglobulin
expression, at least in the progressive phase and very low
MHC I expression [33, 34]. Whether or not the APM is
also affected is not known. Tumour cells in the so-called
646 Cancer Immunol Immunother (2010) 59:643–651
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b2-microglobulin [34, 35]. This suggests that loss of both
MHC I and b2-microglobulin expression is important for
CTVT transmission and that its regulation is likely to
have an epigenetic mechanism. Remarkably, MHC I
suppression in CTVT is not complete and, in fact, is
modulated presumably to prevent recognition and killing
by NK (natural killer) cells [4]. This ‘‘ﬁne tuning’’ may
be the result of the powerful selective bottleneck during
transmission of CTVT, whereby any transmitted cell
lacking MHC I would be rapidly eliminated by NK cells.
Hence, selection might have occurred against deletion or
deleterious mutations in MHC I genes in the case of
CTVT. Whether these kinds of positive and negative
selective pressures on the MHC I genes are also exerted
in other cancer cells is unclear at present. If widespread,
such a ﬁnely balanced regulation of MHC I expression
would provide strong evidence for a primary role of the
immune system in cancer evolution.
Reduced MHCII expression
MHCII expression is more variable than expression of
MHC I, both within an individual immune system and at
the population level, and most cancers and normal tissues
do not express MHCII. MHCII is essentially a receptor that
enables lymphocytes to communicate with one another,
and is therefore expressed only on a limited range of cells.
In contrast, MHC I allows cytotoxic T cells (CTL) to target
any cell infected with a virus or other intracellular parasite,
and therefore has ubiquitous expression. Nevertheless,
CD4
? MHCII-restricted T cells engage in anti-tumour
responses [36], and offer possibilities for therapy [37].
CTVT expresses little MHCII antigens on the cell surface
in the progressive phase, although this phenotype is
reversed in the regressive phase [21]. Interestingly, dogs
that have overcome CTVT are immune to re-inoculation
and have antibodies that recognize antigens on the surface
of CTVT cells, which may drive acute rejection [35, 38].
Expression of MHC class II antigens by CTVT cells is
likely to promote the generation of CTVT-speciﬁc anti-
bodies, suggesting that re-expression of MHCII in the
regressive phase may have an important role in inducing
subsequent protection against re-inoculation. Similar to
MHC I antigens, the regulation of MHCII expression in
CTVT is likely to be epigenetic in nature but in this case it
is unclear why MCH II genes have not undergone deletion
during the evolution of this cancer.
Much of our understanding of MHCII gene expression
derives from the bare lymphocyte syndrome (BLS), a rare
MHCII deﬁciency in which CD4
? T cells fail to develop,
thus increasing susceptibility to infection [39]. The mutated
genes encode three regulatory (RFX) factors that bind to
DNA motifs upstream from the genes encoding the MHC
molecules, and one non-DNA binding protein (CIITA) that
binds the RFX factors together into a regulatory complex.
Thus, the CIITA protein functions as a master switch
controlling MHCII expression, which also regulates MHCI
expression. These factors themselves are not polymorphic,
but their binding sites in the promoter region upstream of
the structural genes have high levels of natural variation,
comparable to that of the MHC structural genes themselves
[40, 41]. Thus, these regions upstream of MHCII genes in
the venereal tumours deserve attention. On the other hand,
the Tasmanian devil’s facial tumour cells appear to express
both MHC class I and II genes, and transmission of this
tumour may be better explained by the lack of MHC
diversity in the devil population. It should, however, be
noted that MHC expression in the tumour cells was
examined only at the mRNA level and one cannot exclude
defects in protein expression or localization at the cell
surface. If, however, lack of MHC diversity in the devil’s
population really explains transmission of the tumour,
DFTD can be used as a negative control to support the
concept of cancer immunoselection: DFTD does not
repress MHC genes because it may not need to.
Epigenetic control of MHC expression
All of the MHC genes mentioned in Table 1 are
doubtless subject to the standard machinery of epigenetic
control, including DNA methylation at CpG islands and
histone methylation, phosphorylation and ubiquitination
[42–44]. In addition, the role of histone deacetylases
(HDACs) in down-regulation of MHCII gene expression
has been well studied and occurs through at least two
major pathways [45]. Recruitment of HDAC1 and
HDAC2 causing disassociation of CIITA from the
MHCII gene promoter and recruitment of HDAC4 via
interaction with RFX-associated ankyrin-containing pro-
tein (RFX-ANK) both cause MHCII silencing. Inhibitors
of HDAC such as trichostatin-A enhance MHC expres-
sion, and thus provide a means for exploring epigenetic
MHC-silencing [45].
Dendritic cells
Among the many possible modes of interventions in anti-
gen presentation, events at dendritic cells are of special
interest because of the ambiguous capacity of these cells, in
activating T cells while at the same time being able to
recruit other down-regulatory T cells, such as Tregs [36].
New work on the autoimmune disease TD1 (type 1 dia-
betes) reveals Deaf1 to be a key regulator of antigen pre-
sentation in these cells [46]. Although not yet studied in
cancer, this molecule would seem to be a promising
Cancer Immunol Immunother (2010) 59:643–651 647
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dendritic cells in CTVT or DFTD.
NK cells and NKT cells
Natural killer [47] and NKT [48] cells (distinct popula-
tions) attack certain tumour cells without prior activation,
hence their name. They express a wide range of stimulatory
and inhibitory receptors, including the KIRs. Some KIRs
are MHC-restricted, and so act more effectively when
tumour cells have reduced MHC expression. Other NK
receptors do not interact with the MHC but may never-
theless mediate immunoselection. The NKG2D (HLA-G-
binding) receptor is a well-characterized non-polymorphic
down-regulatory receptor. HLA-G is a non-variable HLAI-
type protein, found cell surface-bound and in body ﬂuids,
and thought to mediate tumour immune evasion [49]. As
mentioned above, NK-cell activity was not evident with the
occult tumours (annotation in Table 1). The role of NK
cells in CTVT regression is not fully understood but there
is evidence suggesting that their activation is important, at
least in tumours transplanted in SCID mice [50]. Recruit-
ment of NK cells with CTVT killing activity appears to
require high levels of both IL-6 and IL-15 [50].
T-regulatory cells
The role of CD4
?CD25
?FoxP3
? Treg cells in transplan-
tation is a subject of much current interest [51]. These cells
comprise two forms, one generated in the thymus and
naturally occurring and the other adaptive. Their mode of
action may well be competitive uptake of cytokine(s)
needed for proliferation [52]. Thus, mopping up of the
cytokines needed for a positive response would make sense
as a protective mechanism in the transmissible tumours.
Other T cells with immunosuppressive activity include
CD4
? IL-10 secreting cells, CD4
? TGF-b secreting cells
and Th17 cells. There is evidence that CTVT cells them-
selves secrete substantial amounts of the down-regulatory
cytokine TGF-b (see Table 1), which is perhaps expected
of a tumour that shows evidence of histiocytic origin [53,
54]. A high local concentration of TGF-b has been shown
to protect tumour cells from inﬁltrating CTLs, possibly by
suppressing their activity and by contributing to the
tumour’s MHC I and II down-regulation [55]. Progressive
and regressive CTVT cells secrete similar quantity of TGF-
b1, yet they show dramatic differences in MHC expression
[21, 35, 55]. Moreover, CTVT cells seem to be unre-
sponsive to IFN-c produced by CTLs [55], which may, in
part, explain their low MHC I expression levels in the P
phase [56]. It has been proposed that higher levels of IL-6
secreted by inﬁltrating CTLs could counteract the immu-
nosuppressive activity of TGF-b1 and kick start the
regressive phase [57]. However, it is unclear why inﬁl-
trating CTLs should express higher levels of IL-6 at a
certain time during the clinical evolution of CTVT.
The observation that TGF-b1, and perhaps other
immunomodulatory cytokines, is secreted by CTVT cells
[55] might explain why the venereal tumour rarely
metastasizes to internal organs, even though it is perfectly
able to do so in immunocompromised dogs. It is likely that
a threshold of TGF-b1 concentration needs to be reached
within the tumour microenvironment to be protective and
that tumour cells circulating in the blood stream are unli-
kely to reach such levels.
Discussion
In summary, lessons from the panel of animal model sys-
tems suggest that multiple elements contribute to the lack
of cancer immune rejection. They include repression of
MHC class I and perhaps MHCII antigens also, at least in
the case of CTVT [34, 35], concomitant loss of b2-
microglobulin and secretion of immunomodulatory cyto-
kines that promote tolerance. Additional mechanisms, such
as polymorphisms in MHC gene promoters, NK-cell and
NKT-cell activities and modulation of CD4
? Treg cells,
though more speculative, deserve further investigation.
Whether all these mechanisms are solely consequence of
immune selection is not completely clear for some of them
(MHC down-regulation), and may be a consequence of loss
of differentiation typical of cancer cells. Interestingly, re-
expression of MHC I and II molecules in regressive CTVT
coincides with an apparent differentiation of tumour cells
[35]. Hence, de-differentiation of cancer cells towards an
embryonic stem cell-like type may favour immunoevasion
and immune surveillance may, in turn, favour the evolution
of such an undifferentiated state of cancer cells.
The evidence for immunoselection is least clear for
DFTD, where the alternative hypothesis of loss-of-diver-
sity in the host is tenable. The special value of having ﬁve
Table 2 Transplantation of a newly induced methylchloranthrene
sarcoma
B10 F1 B10.D2 F2
3/8 Original F1
line 10/10
2*/8 9/18
B10 sub-line 7/7 3/3 1/4
5/9 3/3 B10.D2 sub-line 3/4
Induced in B10 9 B10.D2F1 mice, and its sublines, derived from
takes in the parental strains. Proportions of takes shown are tumours
grown to 1 mL at the time of killing, within 4 weeks of transplan-
tation [with one exception (asterisk), where the transplant took
8 weeks to grow]
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over such different lengths of time. The F1 tumour trans-
planted to parent usually develops within 4 weeks, prior to
killing (Table 2). The microdose-MCA occult tumours
become evident in mice after 200 days, although the timing
of their emergence is not known in detail. The metastatic
tumours develop over a few weeks. In contrast, both CTVT
and DFTD are ancient, with long exposure to immunose-
lection in serial hosts. These various systems are thus likely
to reveal mechanisms of evasion that differ signiﬁcantly
but may well overlap. It is of particular value to have
CTVT included, because as a ‘‘histiocytic’’ tumour it is
potentially able to express MHC class II and therefore
reveal immunoselection acting on these molecules
(Table 1).
Future work will no doubt further examine the occult
and metastatic MCA tumours, beyond the annotation of
effective and ineffective treatments illustrated in Table 1.
Immunosuppressive drugs should prove informative here.
In the search for inhibitors of organ transplant rejection,
drugs with diverse modes of action have been identiﬁed [3,
58, 59]. These include (a) inhibitors of T cell activation,
such as calcineurin inhibitors, LFA-1 inhibitors and
inhibitors of CD28 binding to CD80/86, (b) T cell depl-
etors, such as inhibitors of T cell proliferation, inhibitors of
nucleotide or purine synthesis and inhibitors of mTor and
(c) blockade of IL-2 binding to IL2 receptor. Any of these
agents might interfere with immunoselection and thus
hinder tumours with reduced antigenicity from emerging.
These are certainly not the only strategies of interest for
probing the latent state of the occult tumours. It would be of
interest, for instance, to apply anti-cancer drugs that target
cell proliferation. These might rid the mouse of its non-
occult tumour cells, and thus allow the occult ones to be
studied at early time points in the course of their selection.
A further possibility would be to apply chemical mutagens
such as ENU (N-ethyl-N-nitrosourea) to evaluate the role of
gene mutation in the response to immunoselection.
Another future topic is TIL. Recent surveys of TILs in
head and neck cancer [60], ovarian and colon cancer [61,
62] report that systematic analysis of CD4
? and CD8
? T
cell inﬁltrates has signiﬁcant prognostic value. More gen-
erally, a multiparameter complex of readouts including
histology, gene expression proﬁling and cytokine proﬁles is
providing improved survival predictions [63]. TILs have
not yet been found in DFTD, presumably because of the
low level of immunity [6] but regressive CTVT is inﬁl-
trated by TILs, supporting a role for these cells in cancer
immunosurveillance [64].
Importantly, the CTVT model shows that, in certain
circumstances, some of the elements important to evade
immune-recognition can be reversed and are therefore
likely to contribute normally to tumour regression. Do any
or all of these various evasion strategies depend on a single
‘‘master switch’’, and is such a switch open to appropriate
intervention? These are central questions in both organ
transplantation and cancer. In CTVT, concomitant down-
regulation of MHC I and II with secretion of immuno-
modulatory cytokines suggests two alternative hypotheses.
Either MHC down-regulation is insufﬁcient on its own to
permit immune evasion and needs an additional layer of
protection, or the secreted cytokines directly or indirectly
control MHC expression. The ﬁrst scenario would provide
a selective advantage if CTVT cells exist in a quasi-stable
epigenetic state, where a proportion of them re-express
MHC molecules at any one time. In that case, secretion of
immunomodulatory cytokines would provide a second line
of protection against immune rejection by promoting tol-
erance [65]. The second scenario more easily explains why
MHC down-regulation is reversible in CTVT. It does not,
however, easily explain why CTVT cannot generally
escape immunorejection once the process has started. We
speculate that only a subset of CTVT cells makes enough
immunomodulatory cytokines to prevent rejection, and
once these cells are gone the tumour enters an irreversible
regressive phase. The role of cancer cell differentiation in
the regression of CTVT and its impact on immune-recog-
nition is also worth investigating. Cancer stem cells are
often deﬁned as a population subset able to grow tumours
when serially transplanted in immunocompromised mice
[66]. However, it has become apparent that the degree of
immunocompetence of the recipient mice plays a role in
establishing the frequency of cancer stem cells in a given
tumour [66]. Little is known on the role, if any, of cancer
stem cells in promoting tumour immunoevasion. Perhaps,
similar to cytokines-secreting cells in CTVT, cancer stem
cells might contribute to evasion in this way. On the other
hand, the immune system may play a role in selecting in
the early phases of tumourigenesis some cancer cells with
undifferentiated and stem cell-like properties. Although
little is known on the (reversible) mechanisms underlying
MHC class I antigen down-regulation in embryonic stem
cells, some of these mechanisms may turn out to be the
same in CTVT and more broadly in other types of cancer
cells. In this respect, CTVT, which is a natural experiment
of cancer cells transplantation, may also provide a valuable
model to investigate the relationship between cancer stem
cells and immune surveillance.
Some of these important questions can now be addressed
by high throughput analyses to compare progressive and
regressive CTVT samples and look for genes differentially
regulated in the two phases. Coupled with genetic
sequencing of the entire CTVT genome and detailed imuno-
histopathological analyses, this approach is likely to reveal
important gene candidates responsible for CTVT regression
and will allow extension of such analyses to human cancers.
Cancer Immunol Immunother (2010) 59:643–651 649
123The available evidence in CTVT suggests that epigenetic
regulation of crucial immunological genes such as MHC I,
MHCII and b2-microglobulin may offer an evolutionary
advantage to cancer cells superior to deletion or mutation of
these genes. If this possibility is veriﬁed and applies in other
cancers, it would open the way to novel therapeutic options
aimed at subverting the epigenetic structure of cancer cells.
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